Cannabinoids in Pediatric Medicine: Evidence-Based Review
Cannabinoid clinical trials pediatric research provides evolving evidence on safety and efficacy in children. This review highlights cautious clinical consideration where conventional treatments fall short. Ongoing studies continue to inform best…
Oregon Cannabis Industry Beats THC Potency Cap in Edibles
Oregon cannabis edible potency remains unregulated after the failed THC cap attempt. This leaves patients exposed to higher-dose edibles increasing risks of adverse effects. Clinicians must counsel patients on dosing and safety amid these regulatory…
Support Doubling Iowa’s Medical Cannabis Dispensaries! – Blog
Iowa medical cannabis dispensaries expansion aims to improve patient access by doubling licensed dispensaries. This legislative progress could reduce treatment delays and travel burdens. Clinicians should stay informed about Iowa medical cannabis…
Bill Allocating Medical Cannabis Funds Passes House – Mountain State Spotlight
West Virginia's medical cannabis program revenue highlights a critical funding gap affecting patient access and clinical research. The unallocated $34 million delays dispensary and provider education development. Understanding medical cannabis program…
Cannabis Compounds Exhibit Potential in Combatting Fatty Liver Disease
Emerging cannabis compounds fatty liver disease research suggests potential metabolic benefits in reducing hepatic steatosis. This early-stage evidence highlights therapeutic possibilities beyond lifestyle changes. Further human trials are needed to…
Daily Digest: Last 6 Hours: Cognitive Safety, Liver Disease Breakthroughs, and the Drug Testing Problem That Won’t Go Away — March 06, 2026
This digest highlights cannabis cognitive aging research alongside promising cannabinoid liver disease studies. It also addresses ongoing drug testing challenges. These insights reflect the evolving landscape of cannabis medicine.
You Guys are Getting Paid
Your endocannabinoid system has been regulating your mood, memory, and immune function for free this whole time while pharmaceutical companies charge you for synthetic alternatives. Further Reading CED Clinic BlogWhy Cannabis Works Evidence WatchCannabis…
Regulatory Digest: Rescheduling Marijuana and Controlled Substances
The controlled substances rescheduling 2026 marks a pivotal regulatory update enabling more rigorous clinical trials and research. This change may facilitate evidence-based guidelines for marijuana use. Clinicians should prepare for evolving policies as…
Daily Digest: Cannabis Adolescent Psychiatric Risk Data Study
This cannabis adolescent psychiatric risk data study highlights new concerns about marijuana use in teens and its association with psychiatric conditions. The developing adolescent brain is particularly vulnerable to cannabis effects, increasing risks…
Daily Digest: Last 48 Hours: Cognitive Safety, End-of-Life Access, and the Impairment Testing Problem — March 06, 2026
This daily digest highlights the impairment testing problem cannabis presents in clinical and policy contexts. It also covers cognitive safety and end-of-life access issues. The focus on impairment testing problem cannabis is crucial for advancing…
